Jury finds Regeneron infringed on rival’s drug patents

By John Golden

No Comment

A federal court will consider a pemanent injunction against Regeneron’s latest drug product after a jury found it infringed on patents held by rival Amgen.

This content is for Westfair Online members only. Please login to view this content. Become a member by Registering Here. If you would prefer to start with a 12 week free trial, Click Here.


About the author

John Golden
The Business Journal’s senior writer, John Golden directs news coverage of the county and Hudson Valley region as Westchester bureau chief. He was an award-winning upstate columnist and feature writer before joining the Business Journal in 2007. He is the author of “Northern Drift: Sketches on the New York Frontier,” a collection of his regional journalism.